All Title Author
Keywords Abstract

PLOS ONE  2013 

Finasteride Inhibits Human Prostate Cancer Cell Invasion through MMP2 and MMP9 Downregulation

DOI: 10.1371/journal.pone.0084757

Full-Text   Cite this paper   Add to My Lib

Abstract:

Introduction The use of the 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride for prostate cancer prevention is still under debate. The FDA recently concluded that the increased prevalence of high-grade tumors among 5-ARI-treated patients must not be neglected, and they decided to disallow the use of 5-ARIs for prostate cancer prevention. This study was conducted to verify the effects of finasteride on prostate cell migration and invasion and the related enzymes/proteins in normal human and tumoral prostatic cell lines. Materials and Methods RWPE-1, LNCaP, PC3 and DU145 cells were cultivated to 60% confluence and exposed for different periods to either 10 μM or 50 μM finasteride that was diluted in culture medium. The conditioned media were collected and concentrated, and MMP2 and MMP9 activities and TIMP-1 and TIMP-2 protein expression were determined. Cell viability, migration and invasion were analyzed, and the remaining cell extracts were submitted to androgen receptor (AR) detection by western blotting techniques. Experiments were carried out in triplicate. Results Cell viability was not significantly affected by finasteride exposure. Finasteride significantly downregulated MMP2 and MMP9 activities in RWPE-1 and PC3 cells and MMP2 in DU145 cells. TIMP-2 expression in RWPE-1 cells was upregulated after exposure. The cell invasion of all four tested cell lines was inhibited by exposure to 50 μM of finasteride, and migration inhibition only occurred for RWPE-1 and LNCaP cells. AR was expressed by LNCaP, RWPE-1 and PC3 cells. Conclusions Although the debate on the higher incidence of high-grade prostate cancer among 5-ARI-treated patients remains, our findings indicate that finasteride may attenuate tumor aggressiveness and invasion, which could vary depending on the androgen responsiveness of a patient’s prostate cells.

References

[1]  Racioppi M, Palermo G, D’Addessi A, Pinto F, Sacco E, et al. (2012) Hot topics in urological health economics. A mini review. Arch Ital Urol Androl 84: 47–52.
[2]  Klein EA, Thompson IM (2012) Chemoprevention of prostate cancer: an updated view. World J Urol 30: 189–194.
[3]  Cussenot O, Azzouzi AR, Nicolaiew N, Mangin P, Cormier L, et al. (2007) Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol 52: 1082–1087.
[4]  Das K, Lorena PD, Ng LK, Lim D, Shen L, et al. (2010) Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocr Relat Cancer 17: 757–770.
[5]  Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B (2003) Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 44: 650–655.
[6]  Rittmaster RS (2011) Chemoprevention of prostate cancer. Acta Oncol 50: 127–136.
[7]  Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, et al. (2005) The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol 174: 2098–2104.
[8]  FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. Available: http://www.fda.gov/Drugs/DrugSafety/ucm2?58314.htm. Accessed 2013 Jan 22.
[9]  Opoku-Acheampong AB, Unis D, Henningson JN, Beck AP, Lindshield BL (2013) Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice. PLoS One 8: e77738.
[10]  Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, et al. (1991) Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 117: 144–150.
[11]  Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827–839.
[12]  Boxler S, Djonov V, Kessler TM, Hlushchuk R, Bachmann LM, et al. (2010) Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer? Am J Pathol 177: 2216–2224.
[13]  Lokeshwar BL (1991) MMP inhibition in prostate cancer. Ann N Y Acad Sci 878: 271–289.
[14]  Delella FK, Justulin LA Jr, Felisbino SL (2010) Finasteride treatment alters MMP-2 and -9 gene expression and activity in the rat ventral prostate. Int J Androl 33: 114–122.
[15]  Justulin LA Jr, Acquaro C, Carvalho RF, Silva MD, Felisbino SL (2010) Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology. Int J Androl 33: 489–499.
[16]  Moroz A, Delella FK, Lacorte LM, Deffune E, Felisbino SL (2013) Fibronectin induces MMP2 expression in human prostate cancer cells. Biochem Biophys Res Commun 430 1319: 1321.
[17]  Golbano JM, Lóppez-Aparicio P, Recio MN, Pérez-Albarsanz MA (2008) Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. Int J Oncol 32: 919–924.
[18]  Byrns MC, Mindnich R, Duan L, Penning TM (2012) Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride. J Steroid Biochem Mol Biol 130: 7–15.
[19]  Wang P, Liu B, Luo JD, Zhang ZG, Ma Q, et al. (2007) Expression of Nkx3.1 enhances 17beta-estradiol anti-tumor action in PC3 human prostate cancer cells. Asian J Androl 9: 353–360.
[20]  Higgins AZ, Cullen DK, LaPlaca MC, Karlsson JO (2011) Effects of freezing profile parameters on the survival of cryopreserved rat embryonic neural cells. J Neurosci Methods 201: 9–16.
[21]  Bass R, Perry B, Langenstroer P, Thrasher JB, Dennis KL, et al. (2009) Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. J Urol 181: 615–619.
[22]  Sawaya ME, Blume-Peytavi U, Mullins DL, Nusbaum BP, Whiting D, et al. (2002) Effects of finasteride on apoptosis and regulation of the human hair cycle. J Cutan Med Surg 6: 1–9.
[23]  Zhang J, Jung K, Lein M, Kristiansen G, Rudolph B, et al. (2002) Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines. Prostate. 50: 38–45.
[24]  Daja MM, Niu X, Zhao Z, Brown JM, Russell PJ (2003) Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines. Prostate Cancer Prostatic Dis. 6: 15–26.
[25]  Ludwig S, Tinwell H, Schorsch F, Cavaillé C, Pallardy M, et al. (2011) A molecular and phenotypic integrative approach to identify a no-effect dose level for antiandrogen-induced testicular toxicity. Toxicol Sci 122: 52–63.
[26]  Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9–34.
[27]  Tsui KH, Chang PL, Feng TH, Chung LC, Hsu SY, et al. (2008) Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells. Anticancer Res 28: 1977–1983.
[28]  Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, et al. (2012) Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget 3: 1455–14571.
[29]  Chignalia AZ, Schuldt EZ, Camargo LL, Montezano AC, Callera GE, et al. (2012) Testosterone induces vascular smooth muscle cell migration by NADPH oxidase and c-Src-dependent pathways. Hypertension 59: 1263–1271.
[30]  Castoria G, D’Amato L, Ciociola A, Giovannelli P, Giraldi T, et al. (2011) Androgen-induced cell migration: role of androgen receptor/filamin A association. PLoS One 6: e17218 doi: 10.1371/journal.pone.0017218.
[31]  Dillard PR, Lin MF, Khan SA (2008) Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 295: 115–120.
[32]  Tilley WD, Bentel JM, Aspinall JO, Hall RE, Horsfall DJ (1995) Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids 60: 180–186.
[33]  Benbrahim-Tallaa L, Webber MM, Waalkes MP (2005) Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation. Environ Health Perspect 113: 1134–1139.
[34]  Tokar EJ, Ancrile BB, Cunha GR, Webber MM (2005) Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Differentiation 73: 463–473.
[35]  Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D (2006) DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett 580: 2294–2300.
[36]  Buchanan G, Craft PS, Yang M, Cheong A, Prescott J, et al. (2004) PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer. Prostate 60: 352–366.
[37]  Opoku-Acheampong AB, Nelsen MK, Unis D, Lindshield BL (2012) The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice. PLoS One doi: 10.1371/journal.pone.0029068.
[38]  Chatterjee B (2003) The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem 253: 89–101.
[39]  Bonaccorsi L, Muratori M, Carloni V, Zecchi S, Formigli L, et al. (2003) Androgen receptor and prostate cancer invasion. Int J Androl 26: 21–25.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal